Last reviewed 2026-05-23 · How we verify

Signifor (pasireotide)

Signifor (pasireotide) is a Somatostatin receptor agonist Small molecule drug developed by Zealand University Hospital. It is currently FDA-approved for Acromegaly in patients inadequately controlled by surgery or radiotherapy, or for whom surgery/radiotherapy is not an option, Cushing's disease in patients for whom surgery is not an option or has failed. Also known as: Signifor.

Pasireotide is a somatostatin receptor agonist that binds to multiple somatostatin receptor subtypes to suppress hormone secretion and inhibit tumor growth.

Pasireotide, also known as Signifor, is used to treat conditions such as Acromegaly, Somatostatin Receptor Positive (SSTR+) tumors, and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). It works by targeting the somatostatin receptors SSTR2, SSTR3, and SSTR5.

At a glance

Mechanism of action

Pasireotide acts as a multi-receptor somatostatin analog with preferential binding to somatostatin receptor subtypes 1, 3, and 5. It suppresses the secretion of growth hormone and insulin-like growth factor-1 (IGF-1) in acromegaly, and inhibits ACTH secretion in Cushing's disease. The drug also has direct antiproliferative effects on neuroendocrine tumor cells.

Approved indications

• Acromegaly in patients inadequately controlled by surgery or radiotherapy, or for whom surgery/radiotherapy is not an option
• Cushing's disease in patients for whom surgery is not an option or has failed

Common side effects

• Hyperglycemia
• Diarrhea
• Abdominal pain
• Nausea
• Cholelithiasis
• Fatigue
• Headache

Key clinical trials

• Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (PHASE3)
• Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (PHASE3)
• Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment (PHASE2)
• Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer (PHASE2)
• Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor (PHASE2)
• Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (PHASE4)
• Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Signifor (pasireotide) CI brief — competitive landscape report
• Signifor (pasireotide) updates RSS · CI watch RSS
• Zealand University Hospital portfolio CI

Frequently asked questions about Signifor (pasireotide)

Related

• Drug class: All Somatostatin receptor agonist drugs
• Target: All drugs targeting Somatostatin receptors (SSTR1, SSTR3, SSTR5)
• Manufacturer: Zealand University Hospital — full pipeline
• Therapeutic area: All drugs in Endocrinology
• Indication: Drugs for Acromegaly in patients inadequately controlled by surgery or radiotherapy, or for whom surgery/radiotherapy is not an option
• Indication: Drugs for Cushing's disease in patients for whom surgery is not an option or has failed
• Also known as: Signifor

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing